Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
At the centre of the deal is SNV4818, currently being evaluated in a Phase 1/2 study. The oral…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…